Skip to main content

Foghorn Therapeutics Inc.

FHTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001822462

No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 121 institutions reported holding it in 13F filings for Q3 2026, worth $168.2M in total; no superinvestor holds it.

Holders of 5% or more of FHTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Foghorn Therapeutics Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of FHTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Flagship Ventures Fund V, L.P.13D/A27.20%20.8M shares–May 24, 20242 filingsJan 13, 2026SEC
Biotechnology Value Fund L P13G/A14.30%8.51M shares+4.31 ppfrom 9.99%May 30, 20243 filingsOct 5, 2026SEC
FMR LLC13G/A11.60%6.79M shares+1.40 ppfrom 10.20%Feb 8, 20217 filingsMay 6, 2026SEC
Flynn James E13G/A8.64%5.14M shares–Sep 20, 20242 filingsMay 14, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

18 Schedule 13D and 13G filings on Foghorn Therapeutics Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on FHTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Oct 5, 20264:27 PM ETBiotechnology Value Fund L Pand 9 others13G/A14.30%8.51M shares+4.31 ppfrom 9.99%Oct 1, 2026SEC
May 15, 20264:09 PM ETBiotechnology Value Fund L Pand 9 others13G/A9.99%5.87M shares–Mar 31, 2026SEC
May 14, 20266:20 PM ETFlynn James Eand 3 others13G/A8.64%5.14M shares–Mar 31, 2026SEC
May 6, 202611:18 AM ETFMR LLCand 1 other13G/A11.60%6.79M shares+1.40 ppfrom 10.20%Mar 31, 2026SEC
Jan 13, 20265:09 PM ETFlagship Ventures Fund V, L.P.and 9 others13D/A27.20%20.8M shares–Jan 9, 2026SEC
Feb 12, 20259:28 AM ETFMR LLCand 1 other13G/A10.20%5.69M shares–Dec 31, 2024SEC
Oct 8, 2024Klarman Family Foundation13G/AOld format–––SEC
Sep 20, 2024Flynn James E13GOld format–New–SEC
Jun 10, 2024FMR LLC13G/AOld format–––SEC
May 30, 2024Biotechnology Value Fund L P13GOld format–New–SEC
May 24, 2024Flagship Ventures Fund V, L.P.13D/AOld format–––SEC
Feb 9, 2024FMR LLC13G/AOld format–––SEC
Feb 9, 2023FMR LLC13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Dec 13, 20218:16 AM ETEli Lilly & Co13GOld format–New–SEC
Apr 19, 2021Kadoch Cigall13GOld format–New–SEC
Feb 8, 2021FMR LLC13GOld format–New–SEC
Feb 4, 2021Klarman Family Foundation13GOld format–New–SEC

Form 144: proposed insider sales

3 notices from officers, directors and other affiliates planning to sell Foghorn Therapeutics Inc. shares, newest first.

Form 144 notices for FHTX
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Sep 16, 20244:40 PM ETCarlos CostaOfficer98.6K$958.9KSep 16, 202410b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Sep 9, 20244:31 PM ETSteven BellonOfficer20.0K$150.6KSep 9, 202410b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC
Aug 16, 20234:33 PM ETSamuel AgrestaOfficer311.3K$2.57MAug 16, 2023Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC